Related Experiment Videos
Anomalies associated with failed methotrexate and misoprostol termination
Nicole T Yedlinsky1, Frank C Morgan, Paul W Whitecar
1Department of Family Practice and Division of Maternal-Fetal Medicine, Womack Army Medical Center, Fort Bragg, North Carolina 28310-5700, USA. Nicole.T.Yedlinsky@us.army.mil
Obstetrics and Gynecology
|May 3, 2005
Summary
Low-dose methotrexate and misoprostol exposure during early pregnancy, even from failed abortions, can lead to significant congenital anomalies and developmental delays in infants. Further research is needed on these teratogen exposures.
Area of Science:
- Reproductive Medicine
- Teratology
- Neonatal Outcomes
Background:
- Methotrexate and misoprostol are commonly used for medical pregnancy termination.
- Limited data exists on low-dose teratogen exposure and neonatal outcomes.
- This study examines neonatal outcomes following failed medical abortion.
Observation:
- Two cases of failed medical abortion with methotrexate and misoprostol were analyzed.
- Exposures occurred in the first trimester of pregnancy.
- Infants presented with intrauterine growth restriction, ventriculomegaly, and multiple congenital anomalies.
Findings:
- First-trimester exposure to methotrexate and misoprostol is associated with adverse neonatal outcomes.
- Congenital anomalies, growth restriction, and developmental delays were observed.
- Even single doses of these medications can pose risks.
Implications:
- Clinicians should be aware of potential teratogenic risks associated with medical abortion agents.
- Enhanced neonatal monitoring is crucial for infants exposed to methotrexate and misoprostol.
- Further studies are warranted to fully understand the long-term effects of low-dose teratogen exposure.